secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-08-19T23:59:59+00:00
Accession:  0001193125-22-225456
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme ups revolver to $575M, repays term loan and revolver with convertible note proceeds
--------------------------------------------------------------------------------

- Revolving credit facility increased by $225M to $575M; all other terms unchanged.
- Company repaid entire term loan facility and all outstanding revolver borrowings using proceeds from previously issued convertible notes.
- Amendment included 11 increase lenders: Bank of America, Wells Fargo, JPMorgan, Citibank, Goldman Sachs, Mizuho, Silicon Valley Bank, and others.
- Conditions included pro forma Consolidated Net Leverage Ratio not exceeding 0.25:1.00 less than the permitted level.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/0001193125-22-225456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522225456/d384340d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-225456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer